NASDAQ:CRBP

Corbus Pharmaceuticals Holdings Stock Predictions

Healthcare > Biotechnology

Buy CRBP

*Your capital is at risk

$7.38

-0.160 (-2.12%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

CRBP Prediction Chart

CRBP Predictions History

Latest community submissions for CRBP.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
seyedsepehr.kimiai.14173	Mar 18, 2019	$7.61 -96.31%	$6.87	X	89.20%	0
JS Pro	Mar 18, 2019	$6.58 -96.81%	$6.87	V	95.80%	0
PumpTheseNumbers Pro	Mar 18, 2019	$6.94 -96.63%	$6.87	X	99.00%	1
JS Pro	Mar 5, 2019	$6.06 -96.49%	$5.76	V	94.80%	0
Gp Merchant @Gp.98898	Mar 4, 2019	$5.26 -97.12%	$6.09	V	86.40%	0
PumpTheseNumbers Pro	Mar 4, 2019	$6.94 -96.20%	$6.09	X	86.00%	0
JS Pro	Feb 21, 2018	$7.57 -96.76%	$7.80	V	97.10%	0
Moleo.Gharib.15518	Dec 18, 2017	$7.05 -96.54%	$6.80	V	96.30%	0
JS Pro	Dec 18, 2017	$7.04 -96.55%	$6.80	V	96.50%	0
Shrayda	Dec 11, 2017	$8.00 -96.22%	$7.05	X	86.50%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CRBP with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CORBUS PHARMACEUTICALS HOLDINGS

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the act...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by